Find in Library

In the era of precision medicine, radiotherapy strategies should be determined based on genetic profiles that predict tumor radiosensitivity. Accordingly, pre-clinical research aimed at discovering clinically applicable genetic profiles is needed. However, how a given genetic profile affects cancer cell radiosensitivity is unclear. To address this issue, we performed a pilot in vitro study by utilizing <i>EGFR</i> mutational status as a model for genetic profile. Clonogenic assays of <i>EGFR</i> mutant (<i>n</i> = 6) and wild-type (<i>n</i> = 9) non-small cell lung carcinoma (NSCLC) cell lines were performed independently by two oncologists. Clonogenic survival parameters SF₂, SF₄, SF₆, SF₈, mean inactivation dose (MID), D₁₀, D₅₀, &#945;, and &#946; were obtained using the linear quadratic model. The differences in the clonogenic survival parameters between the <i>EGFR</i> mutant and wild-type cell lines were assessed using the Mann&#8722;Whitney U test. As a result, for both datasets, the <i>p</i> values for SF₂, SF₄, D₅₀, &#945;, and &#945;/&#946; were below 0.05, and those for SF₂ were lowest. These data indicate that a genetic profile of NSCLC cell lines might be predictive for their radiation response; i.e., <i>EGFR</i> mutant cell lines might be more sensitive to low dose- and low fraction sized-irradiation.